• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 29, 2014

View Archived Issues

Valeant ups the ante, preserves Darpin in Allergan takeover bid

Valeant Pharmaceuticals International Inc. appears to be hunkering down for the long haul in its hostile bid for Allergan Inc. Read More

Biosimilars players will likely consolidate; sales potential still unknown

SEOUL, South Korea – Promising as the biosimilar market appears today, a consolidation that leaves only a handful of global players may be inevitable and the prospects may not be as rosy as they seem, said drug company executives at Bio Korea 2014. Read More

Researchers publish draft proteome maps

Two separate draft catalogs of the human proteome have brought new insights into the relationship between genes and proteins, identifying both proteins that were transcribed from supposedly noncoding regions of the genome, and genes that never got turned into proteins even though they had all the bells and whistles that flag them as bona fide protein-coding genes. Read More

FDA told higher bar needed for pregnancy drug registries

It's time to raise the bar for requiring makers of drugs and vaccines to create pregnancy exposure registries, the FDA was told Wednesday at a public meeting on postapproval evaluation of drug safety during pregnancy. Read More

On the way to ASCO, immuno-oncology firm Armo closes $30M round

While big pharma firms are expected to make the big splash in immuno-oncology at the upcoming American Society of Clinical Oncology (ASCO) meeting, small biotech Armo Biosciences Inc. also will be on hand with a poster on AM0010, a promising interleukin-10 (IL-10)-targeting immunotherapy that helped the Redwood City, Calif.-based firm attract $30 million in series B funding. Read More

GSK's corruption troubles grow; UK Serious Fraud Office starts investigation

SHANGHAI – Glaxosmithkline plc has confirmed the company is under investigation by the UK Serious Fraud Office (SFO). The case is presumed to be related to the almost year-long corruption investigation into GSK China activities that came to a close last week. Read More

Financings

Chimerix Inc., of Durham, N.C., said it completed an underwritten public offering of about 8.4 million shares of its common stock, which included approximately 1.1 million shares sold by the underwriters who exercised their option to purchase additional shares at the offering price of $14.22 per share. Read More

In the clinic

Dyax Corp., of Burlington, Mass., said the first patient was dosed in its phase Ib study of DX-2930 in hereditary angioedema (HAE). Read More

Stock movers

Read More

Other news to note

Intensity Therapeutics Inc., of Westport, Conn., established a cooperative research and development agreement, with the National Cancer Institute to study the efficacy and mechanism of action of its NKT cell agonist-based in situ chemo-vaccination products using in vivo models of cancer. Read More

Pharma: Other news to note

Boehringer Ingelheim AG (BI), of Ingelheim, Germany, reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding the anticoagulant Pradaxa (dabigatran etexilate mesylate) in the amount of $650 million. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe